pioglitazone has been researched along with Hematologic Malignancies in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burton, JD | 1 |
| Castillo, ME | 1 |
| Goldenberg, DM | 1 |
| Blumenthal, RD | 1 |
1 other study available for pioglitazone and Hematologic Malignancies
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma; Caspase Inhibitors; Caspases; Cel | 2007 |